112 related articles for article (PubMed ID: 21318601)
1. Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.
Gluz O; Wild P; Liedtke C; Kates R; Mendrik H; Ehm E; Artinger V; Diallo-Danebrock R; Ting E; Mohrmann S; Poremba C; Harbeck N; Nitz U; Hartmann A; Gaumann A
Breast Cancer Res Treat; 2011 Apr; 126(3):643-51. PubMed ID: 21318601
[TBL] [Abstract][Full Text] [Related]
2. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
Basilio-de-Oliveira RP; Pannain VL
World J Gastroenterol; 2015 Jun; 21(22):6924-30. PubMed ID: 26078569
[TBL] [Abstract][Full Text] [Related]
3. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer.
Zhou S; Wang GP; Liu C; Zhou M
BMC Cancer; 2006 Sep; 6():231. PubMed ID: 17010208
[TBL] [Abstract][Full Text] [Related]
4. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
Rubatt JM; Darcy KM; Hutson A; Bean SM; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
Gynecol Oncol; 2009 Mar; 112(3):469-74. PubMed ID: 19135712
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome.
Dales JP; Garcia S; Andrac L; Carpentier S; Ramuz O; Lavaut MN; Allasia C; Bonnier P; Charpin C
Int J Oncol; 2004 May; 24(5):1197-204. PubMed ID: 15067342
[TBL] [Abstract][Full Text] [Related]
6. Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity.
Gluz O; Wild P; Meiler R; Diallo-Danebrock R; Ting E; Mohrmann S; Schuett G; Dahl E; Fuchs T; Herr A; Gaumann A; Frick M; Poremba C; Nitz UA; Hartmann A
Int J Cancer; 2008 Sep; 123(6):1433-8. PubMed ID: 18561322
[TBL] [Abstract][Full Text] [Related]
7. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy.
Diallo-Danebrock R; Ting E; Gluz O; Herr A; Mohrmann S; Geddert H; Rody A; Schaefer KL; Baldus SE; Hartmann A; Wild PJ; Burson M; Gabbert HE; Nitz U; Poremba C
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):488-97. PubMed ID: 17255270
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis.
Dubinski W; Gabril M; Iakovlev VV; Scorilas A; Youssef YM; Faragalla H; Kovacs K; Rotondo F; Metias S; Arsanious A; Plotkin A; Girgis AH; Streutker CJ; Yousef GM
Hum Pathol; 2012 Jul; 43(7):1037-43. PubMed ID: 22204709
[TBL] [Abstract][Full Text] [Related]
9. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Erber R; Gluz O; Brünner N; Kreipe HH; Pelz E; Kates R; Bartels A; Huober J; Mohrmann S; Moustafa Z; Liedtke C; Möbus V; Augustin D; Thomssen C; Jänicke F; Kiechle M; Kuhn W; Nitz U; Harbeck N; Hartmann A
Breast Cancer Res Treat; 2015 Apr; 150(2):279-88. PubMed ID: 25721604
[TBL] [Abstract][Full Text] [Related]
10. Microvessel Landscape Assessment in Pancreatic Ductal Adenocarcinoma: Unclear Value of Targeting Endoglin (CD105) as Prognostic Factor of Clinical Outcome.
Lytras D; Leontara V; Kefala M; Foukas PG; Giannakou N; Pouliakis A; Dervenis C; Panayiotides IG; Karakitsos P
Pancreas; 2015 Jan; 44(1):87-92. PubMed ID: 25058886
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic and predictive impact of protein expression profiling in high risk breast cancer patients treated with high-dose chemotherapy].
Diallo-Danebrock R; Ting E; Gluz O; Herr A; Mohrmann S; Geddert H; Gabbert HE; Nitz U; Poremba C
Verh Dtsch Ges Pathol; 2007; 91():187-96. PubMed ID: 18314614
[TBL] [Abstract][Full Text] [Related]
12. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma.
Behrem S; Zarkovic K; Eskinja N; Jonjic N
Croat Med J; 2005 Jun; 46(3):417-22. PubMed ID: 15861521
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
14. [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers].
Charpin-Taranger C; Dales JP; Garcia S; Andrac-Meyer L; Ramuz O; Carpentier-Meunier S; Bonnier P
Bull Acad Natl Med; 2003; 187(6):1129-45; discussion 1145-6. PubMed ID: 14978873
[TBL] [Abstract][Full Text] [Related]
15. Endoglin (CD 105) as a potential prognostic factor in neuroblastoma.
Ćavar S; Jelašić D; Seiwerth S; Milošević M; Hutinec Z; Mišić M
Pediatr Blood Cancer; 2015 May; 62(5):770-5. PubMed ID: 25683142
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta binding receptor endoglin (CD105) expression in esophageal cancer and in adjacent nontumorous esophagus as prognostic predictor of recurrence.
Bellone G; Solerio D; Chiusa L; Brondino G; Carbone A; Prati A; Scirelli T; Camandona M; Palestro G; Dei Poli M
Ann Surg Oncol; 2007 Nov; 14(11):3232-42. PubMed ID: 17682823
[TBL] [Abstract][Full Text] [Related]
17. CD105 expression is an independent predictor of survival in patients with endometrial cancer.
Erdem O; Taskiran C; Onan MA; Erdem M; Guner H; Ataoglu O
Gynecol Oncol; 2006 Dec; 103(3):1007-11. PubMed ID: 16854456
[TBL] [Abstract][Full Text] [Related]
18. CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival.
Davidson B; Stavnes HT; Førsund M; Berner A; Staff AC
Breast; 2010 Dec; 19(6):493-8. PubMed ID: 21078485
[TBL] [Abstract][Full Text] [Related]
19. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.
Randall LM; Monk BJ; Darcy KM; Tian C; Burger RA; Liao SY; Peters WA; Stock RJ; Fruehauf JP
Gynecol Oncol; 2009 Mar; 112(3):583-9. PubMed ID: 19110305
[TBL] [Abstract][Full Text] [Related]
20. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma.
Saad RS; El-Gohary Y; Memari E; Liu YL; Silverman JF
Hum Pathol; 2005 Sep; 36(9):955-61. PubMed ID: 16153457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
